Search

Displaying results 1251 - 1260 of 8573 in total
  1. Drug

    Colchicine

    go.drugbank.com/drugs/DB01394
    ApprovedInvestigational

    Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus."[A183611] Its use was first approved by the FDA in 1961. … [L47591] It has also been investigated in other inflammatory and fibrotic conditions.[A183602]

  2. Drug

    Terlipressin

    go.drugbank.com/drugs/DB02638
    ApprovedInvestigational

    [L43217] As a potent vasopressor, terlipressin has been investigated in various shock states and conditions with diminished vasomotor tone. … [A2601, A2602, A2603, A2604, A2605] It was also studied in hepatorenal syndrome (HRS) and variceal bleeding.[A252672] The drug was first approved by the FDA in September 2022.[L43217]

  3. Drug

    Amlexanox

    go.drugbank.com/drugs/DB01025
    ApprovedWithdrawn

    Amlexanox as a topical paste is a well tolerated treatment of recurrent aphthous ulcers.

  4. Drug

    Indian frankincense

    go.drugbank.com/drugs/DB14275
    ApprovedInvestigational

    Indian frankincense is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Mixtures: ACTS38 BoswelliaGel (100ml)
  5. Drug

    Galcanezumab

    go.drugbank.com/drugs/DB14042
    ApprovedInvestigational

    [L42060] It is unknown if galcanezumab has an effect on pregnancy outcomes. A pregnancy exposure registry has been established to evaluate the safety of this drug in pregnant women.[L42060] … [A33112] Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of migraine and the treatment of episodic cluster headache.

  6. Drug

    Cerliponase alfa

    go.drugbank.com/drugs/DB13173
    ApprovedInvestigational

    [L51319] On April 27, 2017, cerliponase alfa was first approved by the FDA as the first treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), also known as TPP1 deficiency. … [A264354, A264369] As a recombinant human TPP1, cerliponase alfa is used as an enzyme replacement therapy to restore the levels of TPP1 in patients with CLN2.[L51339]

  7. Drug

    Dorzolamide

    go.drugbank.com/drugs/DB00869
    ApprovedInvestigational

    [A1303] Unlike oral CA inhibitors, dorzolamide has negligible effects of acid-base or electrolyte disturbances and other systemic adverse effects. … [A1304] First marketed in 1995,[A190624] dorzolamide is available in ophthalmic solutions as monotherapy marketed as Trusopt [L11377] or in combination with [timolol] as Cosopt PF.[L11380]

  8. Drug

    Suprofen

    go.drugbank.com/drugs/DB00870
    ApprovedWithdrawn

    It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic. It is no longer approved for use in the United States.

  9. Drug

    Ornithine

    go.drugbank.com/drugs/DB00129
    ApprovedInvestigationalNutraceutical

    L-Ornithine allows for the disposal of excess nitrogen and acts as a precursor of citrulline and arginine.

  10. Drug

    Nelarabine

    go.drugbank.com/drugs/DB01280
    ApprovedInvestigational

    [A258719] Nelarabine was first granted accelerated approval by the FDA on October 28, 2005, and was manufactured under the trademark name ARRANON by GlaxoSmithKline. … not responded to or has relapsed following at least two chemotherapy regimens.